The effects of interruption of dopaminergic transmission or sustained blockade of dopamine receptors by neuroleptics on the dopamine D3 receptor in the shell of the nucleus accumbens were investigated in rats. In this brain area the D3 receptor is abundant and may mediate antipsychotic drug effects. The D3 receptor density and mRNA abundance were evaluated with 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin and by quantitative PCR or image analysis ofin situ hybridization signals, respectively. Unilateral dopamine neuron degeneration by 6-hydroxydopamine or sections triggered, after a few days, a marked decrease (up to 50%) in D3 receptor binding and mRNA in the nucleus accumbens. In contrast, a 2-week treatment with the neuroleptic haloperidol (20 mg/kg) had no effect on D3 receptor density and mRNA but enhanced D2 receptor density and mRNA level by >50%. In addition, tolerance to the haloperidol-induced change of neurotensin mRNA mediated by the D2 receptor developed, but there was no tolerance to the opposite change mediated by the D3 receptor. Reserpine, a monoamine-depleting drug with antipsychotic activity, did not modify D3 receptor mRNA. These observations reinforce the idea that the D3 receptor may be an important target for neuroleptics whose antipsychotic actions, but not extrapyramidal motor actions, do not display tolerance. The D3 receptor mRNA level was also decreased by a unilateral injection in dopamine cell body areas of colchicine, a drug blocking the anterograde axonal transport, or by baclofen, a type A -aminobutyric acid receptor agonist reducing dopamine neuron activity, but not by sustained blockade of Dil-like and D2-like, neurotensin, or cholecystokinin receptors. We therefore propose that an anterograde factor present in mesolimbic dopaminergic neurons, but distinct from dopamine and known peptide cotransmitters, plays a positive role on transcription of the D3 receptor gene.
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The dopamine (DA) D3 and D4 receptors, two receptors displaying similarities with the DA D2 receptor, have been recently identified. Their high sequence homology (1, 2), similar coupling to guanine nucleotide binding proteins (3) (4) (5) , and recognition by antipsychotic drugs (1, 2, 6, 7) have raised questions regarding the functional significance of this diversity.
Receptor diversity may allow a single neurotransmitter to exert distinct influences on various target neurons. In this respect, D3 and, even more, D4 receptors seem to be expressed in much more restricted brain areas and in distinct neuronal populations as compared to the D2 receptor (1, 2, 8) . The D4 receptor, however, seems to mediate, like the D2 receptor, inhibition of adenylyl cyclase (5) . In the case of the D3 recepThe publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
tor, the signaling system in cerebral neurons remains to be identified but its stimulation may trigger responses opposite to those mediated by the D2 receptor. Thus, in the nucleus accumbens, blockade of the two receptor subtypes by neuroleptics enhances neurotensin/neuromedin (NT) gene expression in D2 receptor-rich areas such as the cone part (also called septal pole) of the shell but nearly abolishes it in neurons of the ventromedial part of the shell expressing exclusively the D3 receptor (9) .
In addition, receptor diversity may allow a differential modulation of the efficiency of dopaminergic transmission in distinct neuronal populations if distinct mechanisms regulate the expression of the various receptor subtypes. The behavioral and biochemical supersensitivity to DA agonists that occurs after impairment of DA neurotransmission and tolerance to DA antagonists are accompanied by an upregulation of D2 receptor expression in brain (reviewed in refs. [10] [11] [12] . The process of neuroleptic-induced upregulation in receptor density has recently been shown to be associated with an increased D2 receptor mRNA level (13) (14) (15) (16) . In contrast, no tolerance to the antipsychotic effects of these drugs seems to develop (17) , suggesting that a subpopulation of D2-like receptors subserving the antipsychotic effects is not subject to antagonistinduced upregulation.
In the case of the D4 receptor, the extremely low abundance of its gene transcripts in brain and the lack of a selective receptor ligand still make it difficult to study regulation of its expression. This does not apply, however, to the D3 receptor, whose gene transcripts can be rather easily detected by in situ hybridization-namely, in nucleus accumbens (8, 9) -and that can be reliably labeled in membrane binding or autoradiographic studies using 7-[3H] hydroxy-N,N-di-n-propyl-2-aminotetralin ([3H]7-OH-DPAT) (18) . We have studied here changes in D3 receptor mRNA and binding sites occurring mainly as a result of sustained interruption of DA transmission elicited by 6-hydroxydopamine (6-OHDA), a catecholamine neuron-ablating neurotoxin, by DA receptor antagonists or by reserpine, a monoamine-depleting agent. (18) . RESULTS Effects of 6-OHDA Lesion and Hemisection on D3 and D2 Receptor Expression. Three weeks after unilateral 6-OHDA infusion, the extent of the lesion was assessed on selected rats displaying apomorphine-induced contralateral rotations. The lesion produced a loss of 90% ± 5% and 84% ± 5% (n = 12; P < 0.01 by Mann-Whitney U test) of the DA transporter mRNA abundance in the substantia nigra and ventral tegmental areas, respectively. In the ipsilateral ventromedial shell of the nucleus accumbens, there were concomitant reductions of D3 receptor binding and mRNA and of NT mRNA (Fig. 1) . Analysis of autoradiograms indicated that D3 receptor and NT mRNAs, a putative index of D3 receptor function (9), decreased by 26% ± 2% (Table 1 ) and 38% ± 5% (n = 6; P < 0.005 by Mann-Whitney U test), respectively, as compared to the contralateral side. In contrast, NT mRNA expression was unchanged in the septum or cone subdivision of nucleus accumbens (Fig. 1C) showed that a brain hemisection at the level of the medial forebrain bundle produced a similar effect that was maximal after 5 days (Fig. 2) . In contrast, D2 receptor mRNA increased Proc. NatL Acad ScL USA 92 (1995) by 48% ipsilaterally in nucleus accumbens of 6-OHDAlesioned rats (Fig. 3 Left). In 6-OHDA-lesioned rats (Fig. 3 Left), the binding of [3H]7-OH-DPAT, a D3 receptor ligand (18) , was decreased ipsilaterally in the nucleus accumbens to the same extent as D3 receptor mRNA (-54%); the decrease was slightly less pronounced in the olfactory tubercle (-33%) and was insignificant in the striatum (-4%). By comparison, D2 receptor binding (Fig. 3 Left), evaluated with [125I]iodosulpride which essentially labels this receptor subtype (18) , was strongly enhanced in nucleus accumbens (+42%). D2 receptor mRNA (Fig. 3 Left) was also enhanced significantly in the ipsilateral accumbens (+48%). Fig. 2 , are expressed as % change over contralateral side for 6-OHDA and over vehicle-treated rats for haloperidol. *, P < 0.05; **, P < 0.01 according to a paired (6-OHDA) or unpaired (haloperidol) Student's t test.
MATERIALS AND METHODS
Effects of Chronic Drug Treatments. Haloperidol, a D2-like receptor antagonist, administered i.p. for 2 weeks, did not modify significantly either D3 receptor binding in any of the analyzed brain areas or D3 receptor mRNA level in the ventromedial part of the nucleus accumbens shell (Fig. 3 Right) . In contrast, [125I]iodosulpride binding was significantly en- hanced in all areas, particularly in the nucleus accumbens where the increase was by 66% and the D2 receptor mRNAwas similarly enhanced by 61% (Fig. 3 Right) .
D3 receptor mRNA level in the same area of nucleus accumbens (Table 1) was not significantly modified by 5-day treatments combining haloperidol and the D1-like receptor antagonist SCH 23390 alone or in combination with SR 48692, a neurotensin receptor antagonist (26) . A 5-day treatment was used in this series of experiments because lesion studies have shown maximal effects on D3 receptor expression at this time (Fig. 2) . In animals receiving for 5 days the two cholecystokinin receptor antagonists devazepide (27) and L-365,260 (28) , in addition to the two DA receptor antagonists, D3 receptor mRNA was elevated but reserpine was without effect (Table   1 ). In contrast, unilateral injection into the substantia nigra/ ventral tegmental area complex of colchicine, an inhibitor of axonal transport, or a 5-day systemic administration of baclofen, a type A -y-aminobutyric acid receptor agonist, decreased significantly D3 receptor mRNA (Table 1; Fig. 4 ). In the ventromedial part of the nucleus accumbens shell, which expresses selectively the D3 receptor (9) , NT gene expression was decreased approximately to the same extent after single or repeated administration of haloperidol (-49% and -58%, respectively), whereas in the cone, which expresses selectively the D2 receptor (9), the NT receptor mRNA level was enhanced by 568% after the single and by 273% after the repeated haloperidol administration (Fig. 5) . 
DISCUSSION
The present study shows that the regulation of D3 receptor gene expression in limbic areas-namely, the shell of nucleus accumbens-after chronic haloperidol treatment or dopaminergic denervation takes place in a manner markedly contrasting that in which regulation of D1 and D2 receptor expression occurs. In striatal areas, the progressive increase in the number of D1 and D2 receptors, which develops after chronic blockade of these receptors (reviewed in refs. [10] [11] [12] or impairment of dopaminergic transmission by reserpine (29) , is well substantiated. This process accounts, at least partially, for the behavioral hypersensitivity to DA agonists and the tolerance to some effects of DA antagonists, the latter exemplified here by the impaired D2 receptor antagonist-mediated stimulation of NT gene expression in the cone subdivision of shell after repeated instead of single haloperidol administration (Fig. 5) . Whereas it was suggested earlier that the enhancement in D2 receptor binding sites could be due to impaired D2 receptor degradation (30) , the parallel elevation of D2 receptor mRNA and D2 receptor binding found in several studies (recently reviewed in ref. 12 ) and confirmed here indicates that an increase in gene transcription rate (or mRNA stability) is involved. In contrast, there was no apparent modification in levels of D3 receptor binding and mRNA or on a D3 receptor-mediated response-i.e., inhibition of NT gene expression in the ventromedial subdivision of the shell of the nucleus accumbens (9)-after chronic administration of haloperidol at a dosage high enough to block D3 receptor. Controversial data were recently reported on the effects of haloperidol on D3 receptor mRNA in mouse (16) and rat (31, 32) brain. It is known that, whereas tolerance develops to some actions of neuroleptics in humans such as extrapyramidal side effects, this is not the case for the antipsychotic effect of these drugs (17) . Hence, the unmodified D3 receptor expression after haloperidol (or reserpine, another antipsychotic) further supports the hypothesis that the D3 receptor might represent an important target for antipsychotic drugs (1) .
The D3 receptor gene expression in limbic areas appears, nevertheless, regulated in a tonic manner by afferent dopaminergic neurons. This is shown by the severe and parallel losses in D3 receptor binding and mRNA after biochemical or mechanical ablation of these neurons. Significant changes were detected as early as one day postsection and were already maximal 5-8 days after either brain hemisection or unilateral injection of 6-OHDA, indicating that they represent a response to harboring neurons rather than indirect adaptative changes (33) . In agreement, visual examination and cell counting showed no apparent cytotoxicity of 6-OHDA in DA projecting areas ( Fig. 1 D and E) . The parallel changes in D3 receptor binding and mRNA after 6-OHDA indicate that the regulation merely affects D3 receptor postsynaptic to DA axons and does not reflect disappearance of autoreceptors on these axons. This conclusion is consistent with the very limited expression of D3 receptor mRNA in ventral tegmental DA neurons synthesizing the autoreceptors (34) .
What is the messenger present in DA neurons and regulating D3 receptor expression in projection areas? The lack of effect of D1-and D2-like receptors blockaded by haloperidol and SCH 23390 and of reserpine treatment indicates that DA itself, or a factor costored in vesicles, is not involved. Peptide cotransmitters may regulate the expression of receptors for the main transmitter, as shown for the calcitonin gene-related peptide present in motoneurons, which increases the number of muscular nicotinic receptors (35) . DA neurons, particularly those projecting to the nucleus accumbens, contain cholecystokinin (36) and neurotensin (37) , but the lack of inhibitory effects of antagonists suggests that these putative cotransmitters do not apparently act as activators of D3 receptor gene expression. This conclusion must be tempered, however, by the Proc. Natt Acad ScL USA 92 (1995) fact that endogenous neurotensin may interact with receptors possibly not blocked by SR 48692 (38 Mesolimbic dopaminergic neurons projecting to the shell of the nucleus accumbens may be implicated in the control of cognitive, emotional, and reward processes (46) . Identification of the anterograde factor they release may, therefore, shed some light on a large diversity of clinical conditions such as mood disorders and cognitive deficits, central to schizophrenia or accompanying Parkinson disease, as well as states of drug dependence.
